Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula

Eyetech Pharmaceuticals

Overview

The purpose of the study is to determine whether pegaptanib sodium (Macugen) is safe and effective in slowing the leakage of fluid within the retina and thereby stabilizing or improving vision when compared to placebo injections. A total of 176 patients will be enrolled

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Diabetic Macular Edema

Interventions

pegaptanib sodium (Macugen)DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients with clinically significant DME, VA 20/50-20/320 in the study eye and 20/100 in the fellow eye

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.